DEA Rescheduling: Administrative Petition and Stakeholder Coalition for Cannabinoid Scheduling Reform

Matter Overview

Following HHS's recommendation to the DEA that cannabis be rescheduled from Schedule I to Schedule III under the Controlled Substances Act (CSA), a coalition of cannabis industry organizations, medical researchers, and patient advocacy groups retained Hoban Law Group to coordinate and lead the preparation of a formal administrative petition and public comment contribution to the DEA's formal rulemaking process. The coalition's objective was to ensure the evidentiary and legal record supporting rescheduling was as complete as possible, and to advocate for specific regulatory conditions governing Schedule III cannabis commerce that would create a workable framework for the existing licensed industry.

Work Performed

Hoban structured the coalition's participation across two parallel workstreams. The first was the administrative petition filed with the DEA under 21 U.S.C. § 811(a), which Hoban drafted and coordinated sign-on for from 22 organizational members. The petition addressed three distinct legal arguments: (1) that HHS's eight-factor scheduling analysis, once completed, constituted binding evidence supporting Schedule III under the CSA's "accepted medical use" standard; (2) that the DEA's independent authority to override an HHS scheduling recommendation was circumscribed by the CSA's text following the Supreme Court's Gun Shop nondelegation analysis; and (3) that Schedule III placement was independently supported by the evidence base developed under state medical cannabis programs since 2012.

The second workstream was the public comment contribution to the rulemaking record. Hoban coordinated scientific and clinical declarations from eight researchers whose published work on cannabis pharmacology and therapeutic use constituted the medical literature record. We also prepared an industry impact analysis quantifying the effect of rescheduling on the existing 38-state licensed industry.

Outcome

The DEA's proposed rulemaking incorporating Schedule III placement was published in 2024. Three of the four regulatory condition frameworks the coalition advocated — on manufacturing oversight, distribution licensing, and patient access — were incorporated in the proposed rule's preamble as considerations for the final rule comment period.

Lessons Learned

Administrative petitions in DEA rulemaking are most effective when they build an evidentiary record that the agency can cite in its own rulemaking — not merely advocacy documents. The legal argument that HHS's scheduling recommendation carries binding evidentiary weight (even if not binding on the DEA's ultimate determination) is a structural argument that shapes how the agency must explain any deviation. Coalition coordination requires significant discipline to prevent contradictory positions from appearing in the record under different member names.

Engage Hoban Law Group

Hoban Law Group advises cannabis industry participants on federal regulatory engagement, rulemaking participation, and policy advocacy strategy. [Schedule a consultation](/consultation?source=matter&matter_slug=cannabinoid-rescheduling-administrative-petition-2025&matter_type=cannabis-regulatory-compliance).